NCCN Annual Conference | Conference

Testing, Treatment Options Added to NCCN CRC Guidelines

March 25th 2019

A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.

Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors

March 24th 2019

Jarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

March 24th 2019

Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.

PARP Inhibition Strategies Refined in Ovarian Cancer Guidelines

March 24th 2019

An updated guideline (version 1.2019) from the NCCN for the management of ovarian cancer recommends specific PARP inhibitors for the treatment of recurrent disease, describes patient selection criteria for each agent, and establishes criteria for PARP inhibitor maintenance therapy.

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 24th 2019

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.

PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy

March 23rd 2019

PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline

March 23rd 2019

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.

NCCN Guidelines Update Increases Role of Genetic Testing in Prostate Cancer

March 23rd 2019

Emmanuel S. Antonarakis, MD, discusses the prevalence of mismatch repair and homologous recombination deficiency genes and how they may play a role in determining a patient’s treatment plan in addition to promising agents that have been introduced to the field in clinical trials.

Dr. Nabors on Evolving Treatment Options for Brain Metastases

March 23rd 2019

Louis B. Nabors, MD, of University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases.

Expert Addresses Therapeutic Updates for Breast Cancer Subtypes

March 22nd 2019

William J. Gradishar, MD, discusses the latest updates in HER2-negative advanced breast cancer and the role of molecular assays in this space.

Germline Testing Emphasized in NCCN Guidelines on Pancreatic Cancer

March 22nd 2019

In recent years, pancreatic has passed breast cancer as the third leading cause of cancer death in the United States, and by 2030 it could be the leading cause.

Frontline Combos Poised to Change NCCN Guidelines in Advanced RCC

March 22nd 2019

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

Dr. Ward on Multigene Testing in Breast Cancer

March 22nd 2019

John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.

Dr. Lyman on the Process for Approving Biosimilars

March 22nd 2019

Gary H. Lyman, MD, MPH, medical oncologist, Fred Hutchinson Cancer Research Center, discusses the differences in approving a biosimilar and the original biologic product during the 2019 NCCN Annual Conference.

Dr. Gubens Discusses the Role of PD-L1 in Patients With NSCLC

March 21st 2019

Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.

Dr. Venook on Evolving Treatment Strategies in CRC

July 22nd 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how treatment strategies have evolved for patients with colorectal cancer.

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

April 4th 2016

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

NCCN Introduces New Vulvar Cancer Guideline

April 4th 2016

A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.

Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

April 4th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

NCCN Refines Recommendations for Breast Cancer Care

April 2nd 2016

At the 2016 NCCN Annual Conference, William J. Gradishar, MD, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.